Home » Stocks » BNGO

BioNano Genomics, Inc. (BNGO)

Stock Price: $9.73 USD -0.29 (-2.89%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $9.83 +0.10 (1.03%) Feb 26, 7:59 PM
Market Cap 2.64B
Revenue (ttm) 7.30M
Net Income (ttm) -37.28M
Shares Out 132.94M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $9.73
Previous Close $10.02
Change ($) -0.29
Change (%) -2.89%
Day's Open 10.08
Day's Range 9.38 - 10.71
Day's Volume 26,459,776
52-Week Range 0.25 - 15.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 3 days ago

BNGO Stock has alot of potential for growth in the long term but its risks currently limit its attractiveness as an investment The post Investors Should Have BNGO Stock on Their Long-Term Watc...

InvestorPlace - 5 days ago

BNGO stock is on the move today without any real company news. Here's what you should know about Bionano Genomics now.

The Dog of Wall Street - 6 days ago

Let's take a look at two companies that Wood has her eye on and has recently added to Ark's large portfolio of funds.

Other stocks mentioned: NNDM, BNGOU
InvestorPlace - 6 days ago

BNGO stock is an investment in the future of gene discovery and therapy as Bionano pushes the boundaries of optical genome mapping tech. The post Leverage the Power of Genetics Tech With Biona...

Other stocks mentioned: BNGOU
Zacks Investment Research - 6 days ago

Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.

GlobeNewsWire - 6 days ago

Proprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr Proprietary scoring...

The Motley Fool - 6 days ago

Yes...and no.

InvestorPlace - 1 week ago

Bionano Genomics makes Saphyr, a genome imaging tool. With BNGO stock doubling over the past month, investors should give the company a look.

The Motley Fool - 2 weeks ago

If you're bullish on genomics, you should be bullish on this stock.

The Motley Fool - 2 weeks ago

The genetic testing specialist could access a major new market.

InvestorPlace - 2 weeks ago

The Alternative Harvest ETF, CIIC Merger, Newell Brands and Bionano Genomics were our top stock trades for Tuesday. Let's look at the charts.

Other stocks mentioned: CIIC, MJ, NWL
InvestorPlace - 2 weeks ago

BNGO stock has continued to shoot higher today on a string of good news that has investors excited about this company's long-term prospects. The post BNGO Stock: Why Bionano Genomics Shares Ra...

InvestorPlace - 2 weeks ago

BNGO stock is up 280% this year as its story begins to unfold. The stock may cool off, but it looks like there are many chapters to come for the firm.

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Scie...

InvestorPlace - 2 weeks ago

Among all the biotech pivots toward the novel coronavirus, BNGO stock represents one of the most sensible. But does that mean shares are a buy?

Zacks Investment Research - 2 weeks ago

Bionano Genomics, Inc. (BNGO) closed at $11.80 in the latest trading session, marking a +1.29% move from the prior day.

InvestorPlace - 2 weeks ago

A dazzling BNGO stock has flown under the radar in 2021, but don't expect shares of this newly-minted mid-cap to remain a secret. The post The Sequence to More Highs is Unfolding in BNGO Stock...

InvestorPlace - 2 weeks ago

BioNano has a promising clinical platform. It needs to generate more revenues before BNGO stock will be worth its current price, however.

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that its Saphyr system is being piloted by the University Health Network's (UHN) Laboratory ...

The Motley Fool - 3 weeks ago

These high-flying stocks have been moneymakers since early November.

Other stocks mentioned: BLNK, SNDL
GlobeNewsWire - 3 weeks ago

SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that presentation recordings from its 5-day Next-Generation Cytogenomics Symposium, which took plac...

Zacks Investment Research - 3 weeks ago

Bionano Genomics, Inc. (BNGO) closed at $11.85 in the latest trading session, marking a -1.41% move from the prior day.

InvestorPlace - 3 weeks ago

Bionano Genomics takes advantage of a spike to sell shares at highs. Cash likely represents about 19% of the BNGO stock market capitalization as a result of two capital raises.

Benzinga - 3 weeks ago

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll...

Other stocks mentioned: MBIO, PHAT, IMVT
Benzinga - 3 weeks ago

Other stocks mentioned: BB, INO
GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a presentation by the Director of the Clinical Cytogenomics Laboratory of Children's Hospital Los A...

The Motley Fool - 1 month ago

This high-flying stock is already one of the biggest winners in the new year.

GlobeNewsWire - 1 month ago

Addition of Microsoft Azure as a High-Performance Computing provider reduces compute cost for genetic disease analysis by more than 50%, compute time by 30% Addition of Microsoft Azure as a Hi...

The Motley Fool - 1 month ago

These popular companies have rallied between 1,000% and 2,400% since late July.

Other stocks mentioned: GME, SOL
The Motley Fool - 1 month ago

Analysts are growing more bullish on the genetic testing specialist's growth potential.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 38,333,352 shares of...

The Motley Fool - 1 month ago

A Wall Street analyst's target-price hike may have had something to do with it.

InvestorPlace - 1 month ago

Bionano's products facilitate research into many diseases and the development of new treatments. Investors should buy BNGO stock.

The Motley Fool - 1 month ago

The biotech's stock sales are alarming investors.

Market Watch - 1 month ago

Bionano Genomics Inc. priced a $200 million underwritten stock offering announced late Tuesday at a discount of $6 a share, selling 33.3 million shares. The stock closed Tuesday at an alltime ...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of...

The Motley Fool - 1 month ago

The genome testing company's investors endured a volatile day.

Market Watch - 1 month ago

Bionano Genomics Inc. on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its commo...

InvestorPlace - 1 month ago

BNGO stock is on the move as an up-and-coming biotech firm leverages the power of optical genome mapping technology. The post Map a Course for Breakthrough Science With BioNano Genomics appear...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the last day of its five-day Next-Generation Cytogenomics Symposium featured presentations by ...

The Motley Fool - 1 month ago

Success tends to bring more success.

Other stocks mentioned: SRNE
The Motley Fool - 1 month ago

Positive reviews from doctors have investors excited about the genome testing company's growth prospects.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day four of its five-day Next-Generation Cytogenomics Symposium featured seven Saphyr users pr...

The Motley Fool - 1 month ago

The genome analysis specialist could help bring about better healthcare outcomes for people with cancer.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day three of its five-day Next-Generation Cytogenomics Symposium featured six Saphyr users pre...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Com...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day two of its five-day Next-Generation Cytogenomics Symposium featured eight Saphyr users pre...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of...

The Motley Fool - 1 month ago

The genetic testing specialist is revealing new insights that could help explain why the coronavirus affects people differently.

About BNGO

Bionano Genomics operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's B... [Read more...]

Industry
Diagnostics & Research
IPO Date
Aug 21, 2018
CEO
R. Erik Holmlin
Employees
97
Stock Exchange
NASDAQ
Ticker Symbol
BNGO
Full Company Profile

Financial Performance

In 2019, BNGO's revenue was $10.13 million, a decrease of -15.59% compared to the previous year's $12.00 million. Losses were -$29.82 million, 61.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is 10.94, which is an increase of 12.44% from the latest price.

Price Target
$10.94
(12.44% upside)
Analyst Consensus: Buy